Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine

American Journal of Pathology

Volumn 158, Issue 4, 2001, Pages 1491-1502

  Vlahou, Antonia ^a,b   Schellhammer, Paul F ^a,b   Mendrinos, Savvas ^a   Patel, Keyur ^a   Kondylis, Filippos I ^a   Gong, Lei ^a   Nasim, Suhail ^a   Wright, George L ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Virginia Prostate Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFENSIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN UBC1; PROTEIN UBC2; PROTEIN UBC3; PROTEIN UBC4; PROTEIN UBC5; PROTEOME; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; HUMAN; HUMAN CELL; IMMUNOASSAY; MASS SPECTROMETRY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; URINALYSIS;

EID: 0035074699     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64100-4     Document Type: Article

References (46)

1. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma
2. Prognostic markers in bladder cancer: A contemporary review of the literature
3. Markers of bladder cancer state of the art
4. The Bard BTA test: Its mode of action, sensitivity, and specificity compared to cytology of voided urine, in the diagnosis of superficial bladder cancer
5. Improved detection of recurrent bladder cancer using the bard BTA stat test
6. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring bladder cancer
7. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment
8. Molecular alteration in bladder cancer
9. Urine cytology, tumour markers and bladder cancer
10. Telomerase activity. Simplification of assay and detection in bladder tumor and urinary exfoliated cells
11. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt™
12. Tumor-derived hyaluronidase: A diagnostic urine marker for high grade bladder cancer
13. Tumor-associated hyaluronic acid: A new sensitive and specific urine marker for bladder cancer
14. Detection of bladder cancer recurrence by microsatellite analysis of urine
15. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine
16. Detection of onco-fetal bladder antigen in urine of patients with transitional cell carcinoma
17. Soluble forms of E-cadherin in urine
18. Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer
19. High resolution two-dimensional gel electrophoresis of proteins
20. From electrophoretically separated proteins to identification: Strategies for sequence and mass analysis
21. Integration of mass spectrometry in analytical biotechnology
22. Overview of peptide and protein analysis by mass spectrometry
23. Protein identification and characterization by mass spectrometry
24. New desorption strategies for the mass spectrometric analysis of macromolecules
25. Bactericidal domain of lactofferin: Detection, quantitation and characterization of lactoferricin in serum by SELDI affinity mass spectrometry
26. ProteinChip surface enhanced laser desorption/ionization mass spectrometry: A novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures
27. Rapid protein profiling of cancer progression directly from human tissue using a protein biochip
28. Laser capture microdissection
29. An enzyme immunoassay for human defensins
30. Towards a comprehensive database of proteins from the urine of patients with bladder cancer
31. A comprehensive protein resource for the study of bladder cancer
32. Loss of adipocyte - Type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinoma
33. Proteome profiling of bladder squamous cell carcinomas: Identification of markers that define their degree of differentiation
34. Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay
35. Urinary protein profiles in patients with urothelial bladder tumours
36. Mechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicity
37. The human b-defensin-1 and a-defensins are encoded by adjacent genes: Two peptide families with differing disulfide topology share a common ancestry
38. Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells
39. β-Defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6
40. Enteric defensins: Antibiotic peptide components of intestinal host defense
41. Presence of defensin in epithelial Langerhans cells adjacent to oral carcinomas and precancerous lesions
42. Immunohistochemical staining of human alpha-defensin-1 (HNP-1), in the submandibular glands of patients with oral carcinomas
43. Immunohistoohemical localization of defensin in human coronary vessels
44. Isolation of human intestinal defensins from ileal neobladder urine
45. Artificial neural networks in the diagnosis of prostate cancer: A pilot study
46. Neural network analysis of clinicopathological and molecular markers in bladder cancer